Search results
Results from the WOW.Com Content Network
The antidepressant effect of ketamine is diminished at 7 days, and most people relapse within 10 days. However, for a significant minority, the improvement may last 30 days or more. [25] [26] [59] [61] One of the main challenges with ketamine treatment can be the length of time that the antidepressant effects last after finishing a course of ...
The results that have been published, about 70 studies, have been overwhelmingly positive in proving the safety and efficacy of ketamine as a mental health treatment. Ketamine was FDA-approved in ...
“Treatment-resistant depression causes great suffering.” A slightly different version of ketamine, called esketamine or Spravato, was approved by the FDA in 2019 for treatment-resistant ...
Ketamine-assisted psychotherapy (KAP) is the use of prescribed doses of ketamine as an adjunct to psychotherapy sessions. KAP shows significant potential in treating mental disorders such as treatment-resistant depression (TRD), anxiety, obsessive–compulsive disorders (OCD), post-traumatic stress disorders (PTSD), and other conditions. [1]
NMDA receptor antagonists induce a state called dissociative anesthesia, marked by catalepsy, amnesia, and analgesia. [1] Ketamine is a favored anesthetic for emergency patients with unknown medical history and in the treatment of burn victims because it depresses breathing and circulation less than other anesthetics.
Current ketamine treatment is in the form of a nasal spray (in the form of esketamine) or injection. Both require that the patient stays in the clinic to be monitored for around 2 hours. This ...
Ketamine crystals on a glass plate. K-hole is the feeling of getting a high enough dose of ketamine to experience a state of dissociation.This intense detachment from reality is often a consequence of accidental overconsumption of ketamine; however, some users consciously seek out the k-hole as they find the powerful dissociative effects to be quite pleasurable and enlightening.
A new study compares ketamine with electroconvulsive therapy in people with treatment-resistant depression. The researchers identify subsets of people who respond better to ketamine and vice versa.